Literature DB >> 3283242

Dissociation between increased surface expression of gp165/95 and homotypic neutrophil aggregation.

J P Buyon1, S B Abramson, M R Philips, S G Slade, G D Ross, G Weissmann, R J Winchester.   

Abstract

Whether homotypic neutrophil aggregation depends on the quantitative increase of gp165/95 molecules (Mac 1, CR3) recruited to the cell surface during activation was studied using mAb of the CD11b group that recognize distinct epitopes encoded by the alpha-subunit of this glycoprotein. After the addition of antibody MN41, neutrophils did not aggregate in response to a chemoattractant, FMLP. Blockade of preexisting surface gp165/95 by mAb MN41, followed by removal of the excess antibody from the mixture, was used to show that the molecules of gp165/95 newly expressed in response to stimulation by a chemoattractant were incapable of effectively mediating the induced cell-cell interactions of aggregation. Flow cytometry studies confirmed that binding of unlabeled antibody MN41 did not block further increases in surface expression of gp165/95 after stimulation with FMLP. These data suggest that molecules of gp165/95 exhibit two functionally distinct forms, one, present on the surface of freshly isolated neutrophils, that becomes competent to mediate the aggregation response upon activation by a stimulus and a second form that can be translocated to the cell surface by the stimulus but is greatly diminished if not lacking in the ability to participate in that aggregation event.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3283242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

Review 1.  The role of CD15-(Le(X))-related carbohydrates in neutrophil adhesion.

Authors:  M A Kerr; S C Stocks
Journal:  Histochem J       Date:  1992-11

2.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Current status review: adhesion molecules and myelomonocytic cell-endothelial interactions.

Authors:  H Rosen; S Gordon
Journal:  Br J Exp Pathol       Date:  1989-06

4.  Rebamipide protects against activation of neutrophils by Helicobacter pylori.

Authors:  N Yoshida; T Yoshikawa; S Iinuma; M Arai; S Takenaka; K Sakamoto; T Miyajima; Y Nakamura; N Yagi; Y Naito; F Mukai; M Kondo
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 5.  PMN adhesion and extravasation as a paradigm for tumor cell dissemination.

Authors:  C W Smith; D C Anderson
Journal:  Cancer Metastasis Rev       Date:  1991-05       Impact factor: 9.264

6.  Activation of human neutrophil LFA-1 (CD11a) by leukotriene B4.

Authors:  R S Shames; E J Goetzl
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

7.  Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion.

Authors:  M H Pillinger; C Capodici; P Rosenthal; N Kheterpal; S Hanft; M R Philips; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 8.  CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions.

Authors:  G D Ross; V Vĕtvicka
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Stimulation of neutrophil adhesion by antibodies recognizing CD15 (Le(X)) and CD15-expressing carcinoembryonic antigen-related glycoprotein NCA-160.

Authors:  S C Stocks; M A Kerr
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

10.  Recruitment of CD11b/CD18 to the neutrophil surface and adherence-dependent cell locomotion.

Authors:  B J Hughes; J C Hollers; E Crockett-Torabi; C W Smith
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.